A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study of Savolitinib plus Durvalumab versus Sunitinib and Savolitinib plus Durvalumab versus Durvalumab in Participants with MET-Driven, Unresectable and Locally Advanced, or Metastatic Papillary Renal Cell Carcinoma (PRCC)